Shanghai Pharmaceuticals reports revenue growth, dividend announcement

Shanghai Pharmaceuticals Holding Co. (HKEX: 2607) announced its 2024 annual results, showcasing a revenue increase of 5.75% year-on-year, reaching RMB275.251 billion. Net profit attributable to shareholders climbed by 20.82% to RMB4.553 billion. This growth was driven by pharmaceutical services, with a 7.47% increase in sales, while pharmaceutical manufacturing sales experienced a 9.62% decline.